Compare VEEE & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEEE | ENVB |
|---|---|---|
| Founded | 1994 | 1994 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.4M |
| IPO Year | 2021 | 2000 |
| Metric | VEEE | ENVB |
|---|---|---|
| Price | $8.19 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.1K | ★ 41.9K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,819,130.00 | ★ $39,914,675.00 |
| Revenue This Year | $1.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.99 | N/A |
| 52 Week Low | $7.90 | $1.17 |
| 52 Week High | $174,752.84 | $795.00 |
| Indicator | VEEE | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 53.19 |
| Support Level | N/A | $1.35 |
| Resistance Level | $9.79 | $1.54 |
| Average True Range (ATR) | 0.53 | 0.10 |
| MACD | 50.02 | 0.00 |
| Stochastic Oscillator | 0.00 | 64.29 |
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power boats to use for fishing, diving and water skiing, and commercial activities including transportation, eco-tours, fishing, and diving expeditions. The company offers various boat models, including Twin Vee 400 GFX2 CC, Twin Vee 280 GFX2 CC, and Twin Vee 260 Center Console STX, among others. Its products are marketed under two brands, Twin Vee for its catamarans, or dual-hull vessels, and Aquasport for its V-hull boats. The company sells its boats through a network of independent boat dealers across North America, the Caribbean, and Central America who resell the boats to the end user, Twin Vee customers.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.